Clinical Trials Directory

Trials / Unknown

UnknownNCT04817046

Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)

Detection of Early-stage Lung Cancer Based on Liquid Biopsy of Peripheral Blood: a Prospective Study

Status
Unknown
Phase
Study type
Observational
Enrollment
467 (estimated)
Sponsor
Peking University People's Hospital · Academic / Other
Sex
All
Age
40 Years – 74 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to develop a lung cancer diagnosis tool using a multi-omics approach based on liquid biopsy.

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening process to determine eligibility of study entry. Peripheral blood, tissue sample and imaging examinations of eligible patients will be collected for further analysis. Data collected will be used to develop a multi-omics lung cancer diagnosis model.

Conditions

Timeline

Start date
2021-02-19
Primary completion
2022-12-31
Completion
2024-12-31
First posted
2021-03-25
Last updated
2021-03-25

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04817046. Inclusion in this directory is not an endorsement.